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OBJECTIVE—To determine whether skin intrinsic ﬂuorescence (SIF) was associated with
autonomic neuropathy and conﬁrmed distal symmetrical polyneuropathy (CDSP) in 111 indi-
viduals with type 1 diabetes (mean age 49 years, mean diabetes duration 40 years).
RESEARCH DESIGN AND METHODS—SIF was measured using the SCOUT DM de-
vice. Autonomic neuropathy was deﬁned as an electrocardiographic abnormal heart rate re-
sponse to deep breathing (expiration-to-inspiration ratio ,1.1). CDSP was deﬁned using the
DiabetesControland ComplicationsTrialclinicalexam protocol (the presenceof twoor moreof
the following: symptoms, sensory and/or motor signs, and/or reduced/absent tendon reﬂexes
consistent with DSP) conﬁrmed by the presence of an abnormal age-speciﬁc vibratory threshold
(using a Vibratron II tester).
RESULTS—The prevalence of autonomic neuropathy and CDSP were 61 and 66%, respec-
tively. SIF was higher in those with autonomic neuropathy (P , 0.0001). In multivariable
analyses controlling for age and updated mean (18-year average) HbA1c, and allowing for other
univariatelyand clinicallysigniﬁcant correlatesof autonomicneuropathy, eachSDchangeinSIF
was associated with a 2.6-greater likelihood of autonomic neuropathy (P = 0.006). Receiver
operating characteristic (ROC) analyses revealed that SIF and updated mean HbA1c accounted
for 80 and 57%, respectively, of the area under the curve (AUC) for autonomic neuropathy. SIF
also was higher in those with CDSP (P , 0.0001) and remained so in multivariable analyses
(oddsratio2.70;P=0.005).ROCanalysesrevealedthatSIFandupdatedmeanHbA1caccounted
for 78 and 59%, respectively, of the AUC for CDSP.
CONCLUSIONS—SIF, a marker of dermal advanced glycation end products, appears to be
more strongly associated with the presence of both CDSPand autonomic neuropathy than mean
HbA1c.
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D
iabetic neuropathy, one of the most
common of the late complications
of diabetes (1), and the leading
cause of nontraumatic amputations (1),
is thought to play a role in the pathogen-
esis of the other late complications of
diabetes (2) and carries a high risk of
mortality (3). The formation of advanced
glycation end products (AGEs) on nerve
tissue has been postulated to play a major
role in the pathogenesis of diabetic neu-
ropathy (4). AGEs are derivatives of the
Maillard reaction of reducing sugars and
protein and typically are characterized by
theirabilitytoformcross-linkswithother
proteins. Certain AGEs ﬂuoresce when
excited with near-ultraviolet and blue
light (5). AGEs, increased in diabetes
as a result of both hyperglycemia and ox-
i d a t i v es t r e s s ,a r eo b s e r v e di nb o t hm y e -
linated and unmyelinated ﬁbers of sural,
peroneal, and saphenous nerves of indi-
viduals with diabetes (6,7) and may con-
tribute to the segmental demyelination of
diabetic neuropathy (8). AGEs also have
been shown to interact with nitric oxide,
leading to neuronal apoptosis (9).
In a substudy of the Diabetes Control
and Complications Trial (DCCT), levels
of skin collagen AGEs were increased in
those with clinical neuropathy (10). Be-
cause certain dermal collagen AGEs, such
as pentosidine and cross-lines, contain
ﬂuorescentcross-links (10), skin intrinsic
ﬂuorescence (SIF) can be quantiﬁed and
act as a novel maker ofAGE accumulation.
Thisledustoinvestigatetheassociationsof
SIF with neuropathy, both autonomic and
conﬁrmed distal symmetrical polyneurop-
athy (CDSP), and how this compares with
cumulative glycemic exposure as deter-
mined by measures of HbA1c over the pre-
vious 18 years of follow-up.
RESEARCH DESIGN AND
METHODS—The Epidemiology of Di-
abetes Complications (EDC) cohort is a
well-deﬁn e dp o p u l a t i o n( n = 658) with
type 1 diabetes diagnosed before the age
of 17 years at the Children’sH o s p i t a lo f
Pittsburgh (11,12). Participants have
been followed since 1986–1988, when
mean age and diabetes duration were 28
and 19 years, respectively. A convenience
sample of 111 participants (96% Cauca-
sian) from the EDC study participated
in this cross-sectional study of noninva-
sively measured SIF, which occurred
~2 years after the 18-year follow-up
exam. All study procedures were ap-
proved by the University of Pittsburgh
Institutional Review Board.
Medical exams took place during the
18-year follow-up. Blood samples were
assayed for lipids, lipoproteins, glycated
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ORIGINAL ARTICLEhemoglobin, and creatinine. HDL choles-
terol was determined by a heparin and
manganese procedure, a modiﬁcation of
the Lipid Research Clinics method (13).
Cholesterol was measured enzymatically.
Non–HDL cholesterol was calculated as
the difference between total cholesterol
and HDL cholesterol. Stable glycosylated
hemoglobin A1 (HbA1) was originally
measured in saline-incubated samples
by microcolumn cation–exchange chro-
matography (Isolab, Akron, OH). On 26
October 1987, the method was changed
to high-performance liquid chromatogra-
phy (Diamat; Bio-Rad Laboratories, Her-
cules, CA). The two methods were highly
correlated (r = 0.95; Diamat HbA1 =
0.18 6 1.00 Isolab HbA1). Beginning in
1998, HbA1c was measured using the
DCA2000 analyzer. Original HbA1
(1986–1998) and A1c (1998–2004) were
converted to DCCT-aligned HbA1cvalues
using regression formulas derived from
duplicate analyses (DCCT HbA1c = [0.83
3 EDC HbA1] + 0.14; DCCT HbA1c =
[EDC HbA1c 2 1.13]/0.81). Cumulative
glycemic exposure was determined using
updated mean HbA1c, calculated by tak-
ing the sum of an individual’sH b A 1c val-
ues over the 18 years of follow-up and
dividing it by the number of HbAlc mea-
surements taken on the individual. (Dur-
ing the nine biennial exams over the
18-year follow-up period, there were an
average of eight measurements.) Urinary
albumin fromtimedurinecollections was
determined immunonephelometrically.
Overt nephropathy was deﬁn e da sa na l -
bumin excretion rate (AER) .200 mg/min
or a history of dialysis/kidney trans-
plantation. Height was measured with a
stadiometer and weight with a balance-
beam scale. BMI was calculated (kg/m
2).
Blood pressure was measured by a random-
zero sphygmomanometer according to a
standardized protocol (14) after a 5-min
rest period and analyzed using the mean
of the second and third readings.
CDSP was deﬁned using the DCCT
clinical exam protocol (15), i.e., at least
two of the following three criteria present
and not attributed to a nondiabetic
cause: symptoms consistent with distal
symmetrical polyneuropathy (DSP); de-
creased (requiring reinforcement) or ab-
sent tendon reﬂexes; and signs of sensory
loss conﬁrmed by the presence of an ab-
normal age-speciﬁc vibratory threshold
(Vibratron II tester) (coefﬁcient of varia-
tion was previously determined to be 8%
[16]). Autonomic neuropathy was de-
ﬁned as an abnormal heart rate response
to deep breathing, i.e., an expiration-to-
inspiration (E/I) ratio ,1.1 in six paced
episodes(17).TheclinicalexamforCDSP
was performed by a trained internist, and
autonomic neuropathy and vibratory
threshold testing was performed by a
trained research assistant.
SIFwasnoninvasivelymeasuredfrom
the skin of the left volar forearm using
a SCOUT DM (VeraLight, Albuquerque,
NM) skin ﬂuorescence spectrometer
(18,19).SIFwasexcitedwithanLEDcen-
teredat405nmandwasdetectedoverthe
emission range of 441–482 nm. The skin
reﬂectance was measured over both the
excitation and emission regions and was
used to compensate for absorbance caused
by melanin and hemoglobin (5). The in-
trinsic ﬂuorescence correction is expressed
in Eq. 1:
fxm ¼
Fxm
R
kx
x R
km
m
where measured ﬂuorescence, Fxm, is di-
vided by reﬂectance values at the excita-
tion and emission wavelengths, Rx and
Rm, respectively. The reﬂectance values
are adjusted by the dimensionless expo-
nents, kx and km. For these analyses,
kx was set to 0.9 and km was set to 0.0.
The resulting intrinsic ﬂuorescence, fxm,
was integrated over the 441- to 496-nm
spectral region to give the SIF sum. The
intrasubject skin variation in SIF assessed
by the SCOUT DM had been previously
determined in a large diabetes screening
study of 2,589 subjects at risk for devel-
oping type 2 diabetes (19). The interday
Hoorn coefﬁcient of variation (fasting vs.
nonfasting) was 6.9% for SCOUT DM–
measured SIF.
As a corollary to this primary study, a
similar investigation was performed with
collaborators at the MedStar Health Re-
search Institute Diabetes Clinic to evalu-
ate the ability of noninvasively measured
SIFtodistinguishthepresenceorabsence
of DSP during routine clinical assess-
ment of patients with type 1 diabetes. The
MedStar Health Research Institute Dia-
betes Clinic was a small, group-practice
setting with three endocrinologists who
mainly saw patients with type 1 and type
2 diabetes. Patients who primarily were
seen and followed by a single clinician
(R.E.R.) were invited to participate in this
pilotstudy.Eligibleparticipantswereseen
for a minimum of 4 years prior to the
index visit when theSIFmeasurementwas
performed. Patients in this clinic were seen
over a mean of 10 years. All procedures
were approved by the MedStar Health
Research Institute Ofﬁce of Research In-
tegrity/Institutional Review Board. In-
formed consent was obtained prior to
any research-related procedure. Routine
assessments independently coded in the
research chart included detailed history
(sex,ethnicity,historyofdiabetes-related
complications, and categories of current
therapies), physical examination (blood
pressure, heart rate, and clinical evalua-
tion for sensory loss consistent with
peripheral neuropathy using the 5.07
[10 g] Semmes-Weinstein monoﬁlament
o nt h ep l a n t a rs u r f a c eo ft h ef e e t[ 2 0 ] ) ,
and laboratory assessments (HbA1c using
the DCCT-aligned DCA 2000+ urine al-
bumin-to-creatinine ratio and lipid panel
performed at the local laboratory). In ad-
dition, medical charts were reviewed to
obtain historical HbA1c values.
The Student t test and x
2 test were
used to examine univariate correlates of
autonomic neuropathy and CDSP. Pear-
son correlations were used to determine
the relationship between SIF and contin-
uous measures of the E/I ratio and toe
vibratory thresholds. Logistic regression
analysis with stepwise selection was
used to determine the independent asso-
ciation of SIF with the prevalence of au-
tonomic neuropathy and CDSP. Odds
ratios are expressed as per SD change in
continuous variables. Receiver operating
characteristic (ROC) curves were used to
determine the discriminative ability of
SIF and mean HbA1c to detect autonomic
neuropathy or lower-limb CDSP. Aikeke
information criterion was used to deter-
mine which models better accounted for
the presence of autonomic neuropathy or
CDSP. Statistical analysis was conducted
using SAS version 9.1 (Cary, NC).
RESULTS—Characteristics of the indi-
viduals who participated in this SIF sub-
study versus the 18-year follow-up exam
participants who did not are presented
in Supplementary Table 1. Those partici-
pating in the SIF substudy were slightly
older but of similar diabetes duration.
They were also in marginally better con-
trol (updated HbA1c 8.4 vs. 8.6%) but
had similar rates of autonomic neuropa-
thy (59.8 vs. 56.6%) and CDSP (64.7 vs.
54.2).
Characteristics of the SIF study par-
ticipants by autonomic neuropathy status
are presented in Table 1. Sixty-six partic-
i p a n t sh a db e e np r e v i o u s l yd i a g n o s e d
with autonomic neuropathy at the time
of SIF measurement. Participants with
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Conway and Associatesautonomic neuropathy were older (aged
51.3 vs. 44.4 years), were of longer dia-
betes duration (41.9 vs. 36.8 years), and
had greater renal damage as measured by
AER (18.2 vs. 4.6 mg/min). They also
were more likely to have a history of
smoking (39.7 vs. 17.5%). CDSP also
was a comorbid complication in the ma-
jority (90.9%) of those with autonomic
neuropathy. Finally, SIF was greater in
those with autonomic neuropathy.
Characteristics of the SIF study par-
ticipants by CDSP status also are pre-
sented in Table 1. There were 73
participants with CDSP. As with auto-
nomicneuropathy,SIFwashigherinthose
with CDSP, and correlates of CDSP were
similar to those for autonomic neuropathy
with the exception of serum creatinine,
blood pressure medication use, and a his-
tory of smoking.
SIF was correlated with most of the
participant characteristics presented in
Table 1 but appeared to demonstrate the
strongest associations with the E/I ratio
of the R-R interval and with the toe vibra-
tory threshold (Supplementary Table 2).
The correlation between the natural log-
transformed SIF and the E/I ratio was
20.47 (P , 0.0001), i.e., the higher the
SIF,themoreabnormaltheE/Iratio.With
the toe vibratory threshold, the SIF corre-
lation was r = 0.50 (P , 0.0001).
Figure 1A compares the discrimina-
tive ability of SIF and updated mean
HbA1c to detect those with autonomic
neuropathy as depicted in ROC curves.
The area under the curve (AUC) for SIF
and autonomic neuropathy was 0.80,
whereas updated mean HbA1c had an
AUC of 0.57. SIF demonstrated good dis-
criminationbetweenthosewithandthose
without autonomic neuropathy, whereas
the discriminative ability of updated
mean HbA1c was slightly better than
chance. Figure 1B compares the discrim-
inative ability of SIF and updated mean
HbA1c to detect those with CDSP. The
AUC for SIF was 0.78 versus an AUC of
0.59 for updated mean HbA1c.S I F
demonstrated a superior ability to detect
CDSP relative to updated mean HbA1c.
Table 2 shows the independent asso-
ciation of SIF and updated mean HbA1c
with autonomic neuropathy and CDSP.
In multivariable regression analyses with
stepwise selection allowing for univariately
Table 1—Characteristics of EDC participants by autonomic neuropathy and CDSP status
Characteristic
Autonomic neuropathy CDSP
Cases Noncases P Cases Noncases P
n 66 43 73 38
SIF (AU)* 0.0098 (0.0024) 0.0075 (0.0015) ,0.0001 0.0097 (0.0025) 0.0075 (0.0015) ,0.0001
Age at SIF measurement (years) 51.3 (7.0) 44.4 (5.9) ,0.0001 51.2 (7.0) 43.7 (5.4) ,0.0001
Duration at SIF measurement (years) 41.9 (6.9) 36.8 (6.2) 0.0001 42.4 (7.2) 35.5 (4.3) ,0.0001
Sex (female) 59.1 (39) 51.2 (22) 0.42 56.2 (41) 55.3 (21) 0.93
Height (cm) 167.6 (10.2) 168.7 (10.6) 0.58 168.1 (10.0) 167.8 (11.0) 0.91
Pulse (bpm) 75.0 (11.2) 71.6 (13.1) 0.16 74.2 (12.0) 72.6 (12.3) 0.52
R-R interval (ms)* 1.06 (0.04) 1.24 (0.11) ,0.0001 1.08 (0.09) 1.21 (0.12) ,0.0001
BMI (kg/m
2) 26.1 (5.0) 26.2 (3.2) 0.96 26.0 (4.9) 26.3 (3.0) 0.76
HbA1c (%) 7.7 (1.7) 7.4 (1.3) 0.46 7.7 (1.7) 7.4 (1.1) 0.24
Updated mean HbA1c (%) 8.5 (1.1) 8.2 (0.89) 0.17 8.5 (1.1) 8.2 (0.89) 0.09
AER (mg/min)* 18.2 (5.6–116.5) 4.6 (3.2–7.0) ,0.0001 18.2 (6.0–102.0) 4.1 (2.9–5.6) ,0.0001
Serum creatinine (mg/dL)* 1.0 (0.9–1.2) 1.0 (0.8–1.1) 0.0004 1.0 (0.9–1.2) 0.9 (0.8–1.0) 0.08
Systolic blood pressure (mmHg) 117.6 (15.7) 109.0 (10.5) 0.001 116.9 (15.5) 109.3 (10.9) 0.005
Diastolic blood pressure (mmHg) 62.9 (10.2) 66.4 (10.6) 0.10 63.3 (10.5) 66.3 (10.2) 0.17
Blood pressure medication use 28.1 (18) 4.9 (2) 0.004 22.9 (16) 13.9 (5) 0.27
HDL cholesterol (mg/dL) 62.6 (18.3) 55.9 (16.2) 0.06 61.3 (18.8) 57.4 (15.4) 0.29
Non–HDL cholesterol (mg/dL) 107.4 (26.3) 113.8 (31.1) 0.26 109.6 (28.6) 110.6 (28.4) 0.87
ACE inhibitor medication use 60.9 (39) 46.3 (19) 0.14 58.6 (41) 47.2 (17) 0.27
History of smoking 39.7 (25) 17.5 (7) 0.02 36.8 (25) 22.2 (8) 0.13
CDSP or autonomic neuropathy 90.9 (60) 25.6 (11) ,0.0001 84.5 (60) 15.8 (6) ,0.0001
Data are means (SD), median (interquartile range), or % (n), as appropriate. *Naturally log-transformed before analysis.
Figure 1—ROC curves for the cross-sectional association of SIF and mean HbA1c to autonomic
neuropathy (A) and CDSP (B).
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Skin ﬂuorescence and diabetic neuropathyand clinically signiﬁcant correlates of
autonomic neuropathy, updated mean
HbA1c was not signiﬁcantly associated
withautonomicneuropathy.Independent
correlates of autonomic neuropathy were
SIF, age, AER, and HDL cholesterol. Each
SD change in SIF was associated with a
2.6-greater likelihood of having auto-
nomic neuropathy. For CDSP, multivari-
able regression analyses with stepwise
selection, allowing for univariately and
clinically signiﬁcant correlates of CDSP,
revealed that updated mean HbA1c was
not signiﬁcantly associated with CDSP;
however, each SD change in SIF was asso-
ciated with a 2.7-greater likelihood of
CDSP. Because SIF exhibited a strong in-
dependent relationship with overt ne-
phropathy in this population (odds ratio
3.17 [95% CI 1.38–7.28]) and given the
known relationship between renal disease
and AGEs, in order to further control for
potential confounding by kidney damage,
analyses were rerun excluding individuals
with a history of overt nephropathy. The
strong independent relationship between
SIF and autonomic neuropathy (2.22
[1.08–4.56]) and CDSP (2.53 [1.22–5.21])
remained.
To determine whether the time in-
terval between the EDC clinical exam and
the measurement of SIF affected the
ﬁndings, analyses were rerun with partic-
ipants stratiﬁed by the median time in-
terval (1.8 years). The mean difference in
SIF levels by autonomic neuropathy sta-
tus was similar in those with a longer
interval between the exam and the SIF
measurement to those with a shorter in-
terval.ThesamewastrueforCDSP.These
results can be found in Supplementary
Table 3.
In the corollary study at the MedStar
Health Research Institute Diabetes Clinic
to evaluate the clinical utility of SIF in a
small pilot population, data from 58
individuals with type 1 diabetes were
available for evaluation. Of the 58 indi-
viduals, 16 had clinical evidence of DSP,
and 42 did not. The naturally logarithmi-
cally transformed SIF showed a trend for
being higherincases withclinicalevidence
ofDSP(P=0.07).Incomparison,therewas
no signiﬁcant difference in updated mean
HbA1c between the cases (8.1%) and non-
cases (7.8%) (P = 0.30).Additional dataon
this cohort is available in Supplementary
Table 4.
CONCLUSIONS—Glycation of pe-
ripheral nerve ﬁbers is thought to play
a role in the development of diabetic
neuropathy. We have shown that SIF, a
marker of AGE accumulation, demon-
strates a strong association with both
autonomic and conﬁrmed DSP. We have
additionally shown that these associa-
tions are independent of traditional risk
factors for neuropathy, such as age, gly-
cemic control, renal function, and smok-
ing, and that SIF was a better indicator of
neuropathy than cumulative glycemic
exposure, as reﬂected by updated mean
HbA1c.
Hypothesized pathogenic mecha-
nisms of peripheral neuropathy include
ischemic effects caused by vascular ab-
normalities, disruption of neuronal me-
tabolism, axonal transport mechanisms
and repair capabilities, glycation of pe-
ripheral nervous system connective tis-
sue, and glycation of Schwann cells or
extracellular matrix(7). Segmental demy-
elination is characterized by breakdown
a n dl o s so fm y e l i no v e raf e ws e g m e n t s
o ft h ea x o na n dr e s u l t si nd e c l i n ei nc o n -
duction velocity and conduction block.
Because myelin facilitates conduction,
we speculate that AGE accumulation
within myelin may interfere with con-
duction. AGE formation in the endoneu-
rium, cytoskeleton, plasma membrane,
Schwann cells, or extracellular matrix
may interfere with axonal elongation
and regeneration, resulting in distal axo-
nal atrophy or degeneration (7).
Our results demonstrating a cross-
sectional association of SIF with diabetic
peripheralneuropathyareconsistentwith
reportsofglycosylatedproteinsandAGEs
in nerve tissue, particularly in those with
diabetes. In eight type 2 diabetic patients
with polyneuropathy, AGEs were found
localized in the endoneurium, perineu-
rium, and microvessels of peripheral
nerve ﬁbers (21). AGE deposition also
was observed in the “cytoplasm of endo-
thelial cells, pericytes, axoplasm, and
Schwann cells of both myelinated and
unmyelinated ﬁbers” in a case-control
study of ﬁve type 2 diabetic subjects and
ﬁve nondiabetic control subjects, with
greater intensity in the diabetic subjects;
higher levels of AGEs correlated with re-
duced density of myelinated ﬁbers (6). In
elderly individuals with type 2 diabetes,
Ryle and Donaghy (7) observed that com-
pared with nondiabetic control subjects,
pentosidine levels were increased in the
cytoskeletal and myelin nerve fractions.
T h e r ea l s ow e r em o r ec r o s s - l i n k e dp r o -
teins in the cytoskeletal fraction of the
nerves in those with diabetes relative to
control subjects (7).
In our population, we observed that
SIF had a much stronger association with
both autonomic neuropathy and CDSP
than cumulative 18-year glycemic expo-
sure. In a substudy ofthe DCCT (10), mea-
sures of glycated collagen demonstrated a
strong association with clinical neuropa-
thy and, in the conventional-treatment
Table 2—Multivariable correlates of autonomic neuropathy and CDSP in EDC participants
Variable
Autonomic neuropathy CDSP
Model 1 Model 2 Model 1 Model 2
Odds ratio (95% CI) Odds ratio (95% CI) Odds ratio (95% CI) Odds ratio (95% CI)
SIF* 3.54 (1.95–6.43) 2.62 (1.31–5.23) 3.52 (1.92–6.46) 2.70 (1.35–5.43)
Age at SIF measurement 2.72 (1.40–5.28) 3.50 (1.71–7.15)
Updated mean HbA1c NS NS
AER* 3.95 (1.77–8.81) 3.63 (1.56–8.45)
HDL cholesterol 2.05 (1.10–3.84) NS
Aikeke information criterion 113.485 98.560 111.754 98.226
Odds ratios are expressed as per SD change continuous variables. Model 1, univariate analysis; model 2, multivariable analysis, using stepwise selection. Stepwise
selection models allowed for age at SIF measurement, SIF, updated mean HbA1c, heart rate, height, serum creatinine, albumin excretion rate, HDL cholesterol, non–
HDL cholesterol, systolic blood pressure, diastolic blood pressure, blood pressure medication use, and a history of smoking. NA, not allowed; NS, nots e l e c t e d .
*Naturally log-transformed before analyses.
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Conway and Associatesarm of the trial, were more strongly corre-
lated with clinical neuropathy than was
cumulative HbA1c or the most recent
HbA1c. Glycated collagen explained 36
and 16%, respectively, of the variability
ofconﬁrmedclinicalneuropathyandnerve
conduction velocity in the intensive-
treatment arm and 51 and 31%, respec-
tively, in the conventional-treatment arm.
After additional adjustment for HbA1c,
this variability was 37 and 14%, respec-
tively, for conﬁrmed clinical neuropathy
and nerve conduction velocity in the
intensive-treatment arm and 67 and
18%, respectively, in the conventional-
treatment arm (10).
To our knowledge, only one other
study has investigated the relationship
between skin ﬂuorescence and diabetic
neuropathy. Meerwaldt and collegues
(22) observed a relationship between skin
autoﬂuorescence, using the AGEReader,
and clinical diabetic neuropathy. Auto-
ﬂuorescence was higher in those with di-
abetes (40% with type 1 diabetes) and,
among those with diabetes, even higher
in those with a history of neuropathic
foot ulceration. It also correlated with
the Wagner score for severity of foot
ulceration. Irrespective of neuropathy sta-
tus, autoﬂuorescence was inversely corre-
lated with heart rate variability, baroreﬂex
sensitivity, and nerve conduction velocity
and amplitude.
A major limitation of this study was
that SIF measurements were taken, on
average, 2 years after clinical assessment
for neuropathy in the EDC population.
Unfortunately, the SCOUT technology
became available during a phase of EDC
when only surveys were being collected.
Because the independent variable of in-
terest, SIF, was measured approximately
2 years after the other clinical data, in-
cluding the outcome variables of interest,
autonomic neuropathy and DSP, we can-
not rule out reverse causation, although
this would seem very unlikely because
AGEshavelongbeenthoughttobeoneof
the major etiologic factors in diabetic neu-
ropathy. The possibility that some partic-
ipants have developed clinical neuropathy
in the intervening period who did not
haveitpreviouslyismorelikely.Thiseffect
would tend to bias against our ﬁndings,
thus our associations could be considered
conservative. When we reanalyzed the
mean difference in SIF by stratiﬁcation ac-
cordingtothemedianlengthoftheinterval
betweenthelastEDCclinicalexamandthe
SIF measurement, we found similar results
for those with a longer (.1.8 years) and
those with a shorter (#1.8 years) time in-
terval. Another limitation of these analyses
is that our population was composed of
middle-aged adults of long diabetes dura-
tion, and, thus, these results are not gener-
alizable to children, young adults, or
individuals with short diabetes duration.
Finally, some limitations arise from the
measurement of SIF itself. In a study of
2,589 subjects at risk for type 2 diabetes,
the interday Hoorn coefﬁcient of variation
was 6.9% (19). A factor that contributes to
this measurement to measurement varia-
tion is skin heterogeneity from freckles,
hair follicles, sweat glands, and wrinkles.
Skin pigmentation differences between pa-
tients and within a patient over time (more
or less tan) are mitigated by measuring the
reﬂectivity of the skin and using the mea-
suredreﬂectancetocorrectthedistortionof
the melanin. It also is possible that diet
could inﬂuence the skin AGE concentra-
tion, and this was not controlled for in
the study. Small studies have shown a re-
lationship between dietary AGEs and se-
rum markers of inﬂammation (23).
Inﬂammatory mediators are induced by
dietary glycotoxins, a major risk factor for
diabetes angiopathy (24). At this point in
time, the role of exogenous AGEs in skin
AGE formation has not been well estab-
lished.
The corollary pilot of investigating
the utility of skin ﬂuorescence in a clinic
population of patients with type 1 di-
abetes followed primarily by a single
clinician investigator demonstrates the
potential applicability of this novel tech-
nology in a clinical environment. Because
of the differences in ascertainment (e.g.,
the research environment of the EDC
included additional measures to conﬁrm
diagnosis of CDSP), the results from one
site cannot be generalized to the other
but rather side by side give a comparative
insight into the real-world clinical envi-
ronment where measures to diagnose
clinical neuropathy are less sensitive and
speciﬁc. Additional studies in the clinical
environment of a broader demographic
and with greater numbers of individuals
are required to generalize the ﬁndings.
In conclusion, we have demonstrated
a strong association between SIF and
peripheral neuropathy in middle-aged
individuals with type 1 diabetes. These
ﬁndings support the hypothesis that
AGEs play a role in the development of
diabetic neuropathy. Prospective studies
are needed to demonstrate the potential
role of SIF in the prediction, assessment,
and monitoring of neuropathy as well as
in the efﬁcacy of therapy for diabetic
neuropathy.
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